Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni.
Fiche publication
Date publication
avril 2017
Journal
PLoS neglected tropical diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ROMIER Christophe
Tous les auteurs :
Anderson L, Gomes MR, daSilva LF, Pereira ADSA, Mourão MM, Romier C, Pierce R, Verjovski-Almeida S
Lien Pubmed
Résumé
Schistosomiasis is a parasitic disease infecting hundreds of millions of people worldwide. Treatment depends on a single drug, praziquantel, which kills the Schistosoma spp. parasite only at the adult stage. HDAC inhibitors (HDACi) such as Trichostatin A (TSA) induce parasite mortality in vitro (schistosomula and adult worms), however the downstream effects of histone hyperacetylation on the parasite are not known.
Mots clés
Acetylation, Animals, Chromatin, genetics, DNA Replication, Down-Regulation, Female, Genome, Helminth, Histone Deacetylase Inhibitors, pharmacology, Histones, genetics, Humans, Hydroxamic Acids, pharmacology, Indazoles, pharmacology, Male, Molecular Docking Simulation, Promoter Regions, Genetic, Pyridones, pharmacology, Schistosoma mansoni, drug effects, Transcriptome, Up-Regulation
Référence
PLoS Negl Trop Dis. 2017 Apr;11(4):e0005539